TY - JOUR
T1 - S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma
AU - Matsunaga, Taketo
AU - Ohtsuka, Takao
AU - Asano, Koichi
AU - Kimura, Hideyo
AU - Ohuchida, Kenoki
AU - Kitada, Hidehisa
AU - Ideno, Noboru
AU - Mori, Yasuhisa
AU - Tokunaga, Shoji
AU - Oda, Yoshinao
AU - Guha, Sushovan
AU - Raimondo, Massimo
AU - Nakamura, Masafumi
AU - Tanaka, Masao
N1 - Funding Information:
From the Departments of *Surgery and Oncology and †Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University; ‡Medical Information Center, Kyushu University Hospital; and §Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; ||Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, The University of Texas Medical School at Houston, TX; and ¶Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL. Received for publication September 28, 2016; accepted August 22, 2017. Address correspondence to: Taketo Matsunaga, MD, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan (e‐mail: mtaketo@surg1.med.kyushu-u.ac.jp). This study was funded by Olympus Corporation. The authors declare no conflict of interest. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000000940
Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Objectives The development of an effective screening method for pancreatic ductal adenocarcinoma (PDAC) is of paramount importance. This study assessed the diagnostic utility in pancreatic diseases of duodenal markers during upper gastrointestinal endoscopy (GIE) or endoscopic ultrasonography. Methods This study prospectively enrolled 299 consecutive participants, including 94 patients with PDACs, 144 patients with other pancreatic diseases, and 61 normal individuals as control subjects. All subjects underwent upper GIE or endoscopic ultrasonography either at Kyushu University Hospital (Fukuoka, Japan) or the Mayo Clinic (Jacksonville, Fla) from October 2011 to July 2014. Duodenal fluid (DF) was collected without secretin stimulation and of carcinoembryonic antigen and S100 calcium-binding protein P (S100P) concentrations were measured. Results Concentrations of S100P in DF were significantly higher in patients with PDAC and chronic pancreatitis than in control subjects (P < 0.01). A logistic regression model that included age found that the sensitivity and specificity of S100P concentration in diagnosing stages 0/IA/IB/IIA PDAC were 85% and 77%, respectively, with an area under the receiver operating characteristic curve of 0.82. Carcinoembryonic antigen concentrations in DF of patients with pancreatic disease did not differ significantly from control subjects. Conclusions Analysis of S100P concentration in DF, in combination with routine screening upper GIE, may facilitate the detection of PDAC.
AB - Objectives The development of an effective screening method for pancreatic ductal adenocarcinoma (PDAC) is of paramount importance. This study assessed the diagnostic utility in pancreatic diseases of duodenal markers during upper gastrointestinal endoscopy (GIE) or endoscopic ultrasonography. Methods This study prospectively enrolled 299 consecutive participants, including 94 patients with PDACs, 144 patients with other pancreatic diseases, and 61 normal individuals as control subjects. All subjects underwent upper GIE or endoscopic ultrasonography either at Kyushu University Hospital (Fukuoka, Japan) or the Mayo Clinic (Jacksonville, Fla) from October 2011 to July 2014. Duodenal fluid (DF) was collected without secretin stimulation and of carcinoembryonic antigen and S100 calcium-binding protein P (S100P) concentrations were measured. Results Concentrations of S100P in DF were significantly higher in patients with PDAC and chronic pancreatitis than in control subjects (P < 0.01). A logistic regression model that included age found that the sensitivity and specificity of S100P concentration in diagnosing stages 0/IA/IB/IIA PDAC were 85% and 77%, respectively, with an area under the receiver operating characteristic curve of 0.82. Carcinoembryonic antigen concentrations in DF of patients with pancreatic disease did not differ significantly from control subjects. Conclusions Analysis of S100P concentration in DF, in combination with routine screening upper GIE, may facilitate the detection of PDAC.
UR - http://www.scopus.com/inward/record.url?scp=85032187931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032187931&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000940
DO - 10.1097/MPA.0000000000000940
M3 - Article
C2 - 28984789
AN - SCOPUS:85032187931
SN - 0885-3177
VL - 46
SP - 1288
EP - 1295
JO - Pancreas
JF - Pancreas
IS - 10
ER -